Seaport Therapeutics, Inc. (NASDAQ:SPTX)
| Market Cap | 1.12B+5.7% |
| Revenue (ttm) | 0 |
| Net Income | -114.40M |
| EPS | -2.14 |
| Shares Out | 53.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 336,175 |
| Open | 21.61 |
| Previous Close | 20.20 |
| Day's Range | 20.02 - 21.73 |
| 52-Week Range | 14.85 - 28.38 |
| Beta | 1.13 |
| Analysts | Buy |
| Price Target | 38.50(+83.68%) |
| Earnings Date | Feb 1, 2027 |
1 qualifying trade · 1 insider · $99.33K bought in the last 90 days
Seaport Therapeutics, Inc. Stock Analysis — InsiderScore
See top-rated InsiderScore stocks ›Seaport Therapeutics, Inc. scored higher than 77% of companies evaluated by InsiderBuying, and ranked 16th out of 96 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Seaport Therapeutics, Inc. bought $99.3K of stock across 1 purchase in the last 90 days, the largest of them $99.3K.
None of these purchases could be measured against an existing holding, so this part of the factor scores on dollars alone.
1 of these purchases was made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.
This category carries 35% of the Insider Score.
About SPTX
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Insider buys and sells on the price
1 year · open-market trades onlyAnalyst consensus
1 firm rating SPTX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 1, 2027Earnings report
Ask Barron about SPTX
$SPTX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in SPTX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SPTX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SPTX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New SPTX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SPTX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SPTX
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $8.60M |
| IWMiShares Russell 2000 ETF | $7.05M |
| VXFVanguard Extended Market ETF | $3.14M |
| PSILAdvisorShares Psychedelics ETF | $2.11M |
| VTWOVanguard Russell 2000 ETF | $1.65M |
| IWOiShares Russell 2000 Growth ETF | $1.58M |
Estimated from each fund’s disclosed top holdings × AUM
SPTX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from SPTX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
Biotech: ranks #16 of 96 scored Biotech stocks · sector average 59.6
What’s Behind the Score
News check: Raymond James initiated Seaport Therapeutics at Strong Buy, a concrete bullish analyst action weighted more heavily than parent company earnings mentions.